Bayer buys European rights to BridgeBio’s ATTR-CM pill

As Bay­er un­der­goes a ma­jor strat­e­gy re­think, with a full-year 2023 up­date slat­ed for Tues­day, the con­glom­er­ate is en­list­ing ex­ter­nal help to boost its car­dio prospects.

The Ger­many-based drug gi­ant is nab­bing the ex­clu­sive li­cense to com­mer­cial­ize Bridge­Bio’s transthyretin amy­loid car­diomy­opa­thy (AT­TR-CM) treat­ment can­di­date aco­ramidis in Eu­rope, the com­pa­nies said Mon­day morn­ing.

In ex­change for $310 mil­lion in up­front and near-term mile­stone pay­ments, Bay­er will get its hands on the oral treat­ment can­di­date. “A com­po­nent of the mile­stone pay­ment will be con­tin­gent up­on reg­u­la­to­ry suc­cess,” Ananth Srid­har, SVP of cor­po­rate de­vel­op­ment for Bridge­Bio Car­diore­nal, said in an emailed state­ment to End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.